Clinical trial
Infliximab (Remicade) for Patients With Acute Kawasaki Disease
NCT00271570 · University of California, San Diego, Other · Completed
Key facts
| NCT number | NCT00271570 |
|---|---|
| Title | Infliximab (Remicade) for Patients With Acute Kawasaki Disease |
| Official title | Infliximab (Remicade) for Patients With Acute Kawasaki Disease Who Fail to Become Afebrile After Intravenous Gamma Globulin Therapy |
| Lead sponsor | University of California, San Diego, Other |
| Collaborators | Centocor, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kawasaki Disease |
| Intervention type | Biological, Drug |
| Interventions | Infliximab (Remicade), Intravenous immunoglobulin (IVIG) |
| Enrollment | 24 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Jan 2, 2006 |
| Last update posted | Jun 14, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: